We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evocutis | LSE:EVO | London | Ordinary Share | GB00B4WKYH05 | ORD 0.01P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0425 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
16/8/2015 09:21 | This will go up now. DL has to sell UKOG. | rwauu | |
16/8/2015 09:20 | This will go up now. DL has to sell UKOG. | rwauu | |
16/8/2015 09:20 | The word is that this will go up now. DL has to sell UKOG shares and step down from EVO. That is why the ramp of HH on his twitter. The only companies that he will be left with will be linigascuba , REM for at least a year and AFRI. | rwauu | |
13/8/2015 11:35 | Just buying recently it seems. Uptick not far away now. | johndee | |
13/8/2015 08:08 | VENN moving up | moreforus | |
13/8/2015 08:07 | ooo some buys that look like sells..... | moreforus | |
13/8/2015 07:30 | The consideration for this transaction will be GBP210,000, to be satisfied by new ordinary shares in the share capital of Venn calculated in accordance with the Disposal Agreement, a royalty of 7.5% on the gross sales of LabSkin(TM) for 3 years from date of acquisition, and a royalty of 25% on the future sale of or out-licence agreements for SYN1113. | moreforus | |
13/8/2015 07:21 | rivaldo Posts: 1,438 Research Opinion: Strong Buy Price: 20.00 Excellent trading updateToday 07:12A very confident trading update today, with H1 revenues in excess of €4m, which puts VENN easily on track to meet - or beat - forecasts of €8m for the year: "Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces a strong first half of 2015 with the Company billing in excess of €4m, up 170% against the same period in 2014 (H1: €1.5m). The Company has demonstrated continued growth throughout 2015 driven by contract wins amounting to over €9m in the period to 30 June 2015. Commenting on the figures, Venn CEO, Tony Richardson said: "Our fee income figures highlight the steady and consistent growth of the Company year on year with both repeat business and organic growth contributing to our excellent results and ability to win projects internationally. Our market continues to grow steadily and with a healthy pipeline of prospects we are well positioned to deliver further growth." Venn will announce its interim results for the six months ended 30 June 2015 on the 22 September 2015." Reply | Recommend | Report | moreforus | |
10/8/2015 13:02 | 4 mill buys 175p paid RTO target for LGC?? | moreforus | |
07/8/2015 09:44 | ALBA up again | moreforus | |
06/8/2015 12:31 | All buys today for a change. | johndee | |
06/8/2015 12:27 | How soon? Been waiting agesssssssssssssssss | dosser2 | |
06/8/2015 10:12 | 1 mill max at 0.1689 | moreforus | |
06/8/2015 10:10 | Yes. Should rise a lot soon! | johndee | |
06/8/2015 10:07 | 1.2 mill buys | moreforus | |
06/8/2015 09:51 | its cheaper than than chip paper! | ryan83 | |
06/8/2015 09:50 | journey of a 1000 miles starts with one step.... cheap as chips down here..... | moreforus | |
06/8/2015 09:49 | chart is pitiful eh! but blue! | ryan83 | |
06/8/2015 09:41 | Some buying finally...2 buys 300,000 and 150,000. | johndee | |
22/7/2015 14:20 | trying to suck a few mugs in here as well jonny boy ?????????????? | singer8 | |
21/7/2015 21:10 | ALBA is looking a great buy now. That may help this company eventually. | johndee | |
17/7/2015 13:46 | tick tock, surely an update is due? | ryan83 |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions